Autopsy report · NCT04124367

IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE

“for strategic and pandemic reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Ran for about 9 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Ever Neuro Pharma GmbH

Sponsor type

Industry

Conditions

Chronic Stroke; Subacute Stroke

Interventions

Cerebrolysin; non-invasive brain stimulation; Placebo; sham intervention

Participants

4

Sites

1

Countries

Austria

Trials that died the same way

• Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
  “for strategic reasons” (76% match in meaning)
• Effect of Global Postural Re-education in Idiopathic Scoliosis
  “Because of the COVID-19 pandemic” (69% match in meaning)
• Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery
  “Because of impact from COVID-19 pandemic” (69% match in meaning)
• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
  “Strategic Reasons” (67% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.